基于網(wǎng)絡(luò)藥理學(xué)及分子對接技術(shù)探討杞菊地黃丸治療干眼癥的作用機制

打開文本圖片集

[Abstract]ObjectiveToexploretheactiveingredientsand mechanismofactionof Qiju Dihuang Pilsinthetreatmentof dry eyebynetworkpharmacologyandmoleculardocking.MethodsTheactiveingredientsofQijuDihuangPilswereobtainedfromTCMSPand PharmacopoeiaofthePeople’sRepublicofChina，andtheirtargetswereconvertedintostandardgenenamesthroughtheUniProtplatfo. DiseasetargetserescrenedfromGeneCards，OMMandDisGeNETdatabases.TheCytoscape3.9.1softwareasusedtoconstructandanalyzetheompoundnetworktoobtaintemainactiveingredientsofthedrugProteininteractionsetwengenesintersectingwithQijuDihuangPillsnddryeereaalydoeGplafondtenmporedintothesoftaretoeenforyargetseesetio geneswereanalyzedforGOfunctionandKEGGpathwayenrichmentusingtheDAVIDdatabase，andfinaly，moleculardockingvalidation wascompletedbyAutoock4.2.6softare.Results149activeingredintsofQijuDiuangPilsand2O14dryeyeargetsweresreeed， withatotafil nin，stigmasterol，soetinndhargesicdedroteinaseB（AK）oosisctor），rote （TP53），nterleukin6（6），nteleukinbeta（B），strognreceptor1（ESR1）Keypathwaysicudedtedvanedglatiodproducts（AGE）-reeptorforadvancedglycationend-products（RAGE）signalingpathwayindiabeticcomplications，phospoiositide3- kinase（PI3K）-AKTsignalingpathwaymitogen-activatedproteinkinase（MAPK）signalingpathway，etc.ConclusionQijuDiuang PillsmaytratdyeytouhectiofqueceionyargessuchasTF5，6dsoItaexetattoryandinhibitapoptosisbyregulating theAGE-RAGEsignalingpathway，PI3K-AKTsignalingpathwayandMAPKsignalingpathway.

徐晨，等，基于網(wǎng)絡(luò)藥理學(xué)及分子對接技術(shù)探討杞菊地黃丸治療干眼癥的作用機制

干眼癥作為一種常見的多因素慢性眼表疾病，其主要病理特性是不穩(wěn)定淚膜引起的不適甚至視力障礙，同時伴有眼表炎癥、損傷及神經(jīng)感覺異常[1]。（剩余14096字）